Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PPM1B | O75688 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19013690 | 0.92 | CYP2C19 (0.42) | CYP2C19PPM1BPTPN1PPP1CCBRD4 | |
| SCHEMBL22723424 | 0.79 | MEN1 (0.46) | CYP2C19PPM1BPTPN1PPP1CC | |
| SCHEMBL8319934 | 0.78 | ALDH1A1 (0.37) | TP53 | |
| SCHEMBL20306770 | 0.77 | MEN1 (0.47) | CYP2C19PPM1BPTPN1PPP1CC | |
| SCHEMBL30461703 | 0.75 | CYP2C19 (0.45) | CYP2C19PPM1BPTPN1PPP1CCBRD4 | |
| SCHEMBL16920613 | 0.74 | CHRNB2 (0.55) | PPM1BPTPN1PPP1CCTP53 | |
| SCHEMBL17322742 | 0.72 | CHRNB2 (0.57) | BRD4TP53 | |
| SCHEMBL20682325 | 0.72 | CYP2C19 (0.39) | CYP2C19PPM1BPTPN1PPP1CCTP53 | |
| SCHEMBL21987247 | 0.72 | TP53 (0.56) | CYP2C19PPM1BPTPN1PPP1CCTP53 | |
| SCHEMBL19013663 | 0.72 | CYP2C19 (0.38) | CYP2C19PPM1BPTPN1PPP1CCTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | EISAI CO., LTD. | 2004-05-13 | — | — | US | disclosed |
| US-6518423-B1 | These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and | EISAI CO., LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | HLA-DRB1, HRH1, HRH2 | CYP2C19 61/4885PPM1B 1280/4885PTPN1 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.